Lindis Biotech has licensed Korjuny (catumaxomab) to Pharmanovia for malignant ascites, offering a targeted immune therapy ...

Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it ...

UK pharma major GSK today announced positive headline results of GLISTEN, the ongoing global Phase III clinical trial ...

Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates.

AbbVie says that Elahere is the first and only folate receptor alpha (FRɑ)-directed antibody drug conjugate (ADC) medicine ...

UK clinical-stage gene specialist Silence Therapeutics (Nasdaq: SLN) yesterday presented end-of-treatment data from its Phase ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) on Monday approved the medicine Filspari (sparsentan) from Vifor France to treat primary immunoglobulin A nephropathy (IgAN).

New York-based ophthalmic technology company Eyenovia is considering its options. Shares in the company dropped by 70% on ...

Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to ...

Following US approval in May this year, South Korea’s Samsung Bioepis and US biotech Biogen have now won approval from the ...

New research published by the European Federation of Industries and Associations (EFPIA) provides in-depth analysis of the ...

French drugmaker Ipsen today announced the long-term efficacy and safety of patients treated with Bylvay (odevixibat) from ...